SPECT Study of the Nigrostriatal Dopaminergic System in Huntington's Disease

ABSTRACT BACKGROUND AND PURPOSE The pathological process of Huntington's disease (HD) preferentially targets spiny neurons in the striatum, with later involvement of the substantia nigra and other structures. The purpose of this study is to investigate the nigrostriatal dopaminergic system in a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuroimaging 2013-04, Vol.23 (2), p.192-196
Hauptverfasser: Hwang, Wen-Juh, Yao, Wei-Jen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 196
container_issue 2
container_start_page 192
container_title Journal of neuroimaging
container_volume 23
creator Hwang, Wen-Juh
Yao, Wei-Jen
description ABSTRACT BACKGROUND AND PURPOSE The pathological process of Huntington's disease (HD) preferentially targets spiny neurons in the striatum, with later involvement of the substantia nigra and other structures. The purpose of this study is to investigate the nigrostriatal dopaminergic system in a genetically confirmed HD family. METHODS We used single photon emission computed tomography (SPECT) with the radiotracers [99mTc]TRODAT‐1 and [123I]IBZM to study the binding potentials of dopamine transporter (DAT) and dopamine D2 receptors in the striatum of 3 symptomatic HD patients, 1 mutation‐negative member of the HD family, and 7 healthy controls. Specific binding potentials were calculated as (striatum‐occipital lobe)/occipital lobe. RESULTS Reduced binding potential of striatal dopamine D2 receptors was found in the 3 symptomatic HD patients. The DAT binding potential was reduced in 1 symptomatic HD patient. We also found that the more severe the clinical status, the lower the DAT and D2 receptor binding potentials, and the larger the bicaudate ratio. CONCLUSIONS We showed that the postsynaptic part of the nigrostriatal pathway was involved. The presynaptic part is usually not affected but could occur in very advanced cases. Our findings suggest that SPECT imaging of D2 receptors is useful for diagnosing and monitoring HD.
doi_str_mv 10.1111/j.1552-6569.2011.00671.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1434033432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1434033432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4671-8dd3574edda44dc5224869b8e4c91f5fc13e8956164ab9d9c51c0d13ec5d40b23</originalsourceid><addsrcrecordid>eNqNkUtvEzEURi0EoqXwF5AlFnQzg69fMyOxQekLiFKkFBWxsRzbExzmEewZkfx7PKRkware2LLPd23fgxAGkkMa7zY5CEEzKWSVUwKQEyILyHdP0Onx4GlaEwEZpSU_QS9i3BBCgVP2HJ1QSgEqSk7RfPnlcnaHl8No97iv8fDD4YVfhz4OwetBN_ii3-rWdy6svcHLfRxci32Hb8Zu8N166Lu3EV_46HR0L9GzWjfRvXqYz9DXq8u72U02v73-OPswzwxPz8xKa5kouLNWc26NoJSXslqVjpsKalEbYK6shATJ9aqylRFgiE2bRlhOVpSdofND3W3of40uDqr10bim0Z3rx6iAM04Y4-wRKKOySB0CkdA3_6Gbfgxd-shECUlKUU5UeaBM6lEMrlbb4Fsd9gqImuSojZocqMmBmuSov3LULkVfP1wwrlpnj8F_NhLw_gD89o3bP7qw-nS7SIsUzw5xnyTtjnEdfipZsEKo-8W1uiLk-_3i22fF2R88oqnt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1325608585</pqid></control><display><type>article</type><title>SPECT Study of the Nigrostriatal Dopaminergic System in Huntington's Disease</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Hwang, Wen-Juh ; Yao, Wei-Jen</creator><creatorcontrib>Hwang, Wen-Juh ; Yao, Wei-Jen</creatorcontrib><description>ABSTRACT BACKGROUND AND PURPOSE The pathological process of Huntington's disease (HD) preferentially targets spiny neurons in the striatum, with later involvement of the substantia nigra and other structures. The purpose of this study is to investigate the nigrostriatal dopaminergic system in a genetically confirmed HD family. METHODS We used single photon emission computed tomography (SPECT) with the radiotracers [99mTc]TRODAT‐1 and [123I]IBZM to study the binding potentials of dopamine transporter (DAT) and dopamine D2 receptors in the striatum of 3 symptomatic HD patients, 1 mutation‐negative member of the HD family, and 7 healthy controls. Specific binding potentials were calculated as (striatum‐occipital lobe)/occipital lobe. RESULTS Reduced binding potential of striatal dopamine D2 receptors was found in the 3 symptomatic HD patients. The DAT binding potential was reduced in 1 symptomatic HD patient. We also found that the more severe the clinical status, the lower the DAT and D2 receptor binding potentials, and the larger the bicaudate ratio. CONCLUSIONS We showed that the postsynaptic part of the nigrostriatal pathway was involved. The presynaptic part is usually not affected but could occur in very advanced cases. Our findings suggest that SPECT imaging of D2 receptors is useful for diagnosing and monitoring HD.</description><identifier>ISSN: 1051-2284</identifier><identifier>EISSN: 1552-6569</identifier><identifier>DOI: 10.1111/j.1552-6569.2011.00671.x</identifier><identifier>PMID: 22211920</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Benzamides - pharmacokinetics ; Corpus Striatum - diagnostic imaging ; Corpus Striatum - metabolism ; dopa-mine transporter ; Dopamine ; dopamine D2 receptor ; Dopamine Plasma Membrane Transport Proteins - metabolism ; Dopaminergic Neurons - diagnostic imaging ; Dopaminergic Neurons - metabolism ; Female ; Humans ; Huntington Disease - diagnostic imaging ; Huntington Disease - metabolism ; Huntington's disease ; Huntingtons disease ; Male ; Medical research ; Middle Aged ; Neural Pathways - diagnostic imaging ; Neural Pathways - metabolism ; Neuroimaging ; Neurology ; Organotechnetium Compounds - pharmacokinetics ; Pyrrolidines - pharmacokinetics ; Radiopharmaceuticals - pharmacokinetics ; Receptors, Dopamine D2 - metabolism ; Reproducibility of Results ; Sensitivity and Specificity ; single photon emission computed tomography ; Substantia Nigra - diagnostic imaging ; Substantia Nigra - metabolism ; Tissue Distribution ; Tomography, Emission-Computed, Single-Photon - methods ; Tropanes - pharmacokinetics</subject><ispartof>Journal of neuroimaging, 2013-04, Vol.23 (2), p.192-196</ispartof><rights>Copyright © 2011 by the American Society of Neuroimaging</rights><rights>Copyright © 2011 by the American Society of Neuroimaging.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4671-8dd3574edda44dc5224869b8e4c91f5fc13e8956164ab9d9c51c0d13ec5d40b23</citedby><cites>FETCH-LOGICAL-c4671-8dd3574edda44dc5224869b8e4c91f5fc13e8956164ab9d9c51c0d13ec5d40b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1552-6569.2011.00671.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1552-6569.2011.00671.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22211920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hwang, Wen-Juh</creatorcontrib><creatorcontrib>Yao, Wei-Jen</creatorcontrib><title>SPECT Study of the Nigrostriatal Dopaminergic System in Huntington's Disease</title><title>Journal of neuroimaging</title><addtitle>J Neuroimaging</addtitle><description>ABSTRACT BACKGROUND AND PURPOSE The pathological process of Huntington's disease (HD) preferentially targets spiny neurons in the striatum, with later involvement of the substantia nigra and other structures. The purpose of this study is to investigate the nigrostriatal dopaminergic system in a genetically confirmed HD family. METHODS We used single photon emission computed tomography (SPECT) with the radiotracers [99mTc]TRODAT‐1 and [123I]IBZM to study the binding potentials of dopamine transporter (DAT) and dopamine D2 receptors in the striatum of 3 symptomatic HD patients, 1 mutation‐negative member of the HD family, and 7 healthy controls. Specific binding potentials were calculated as (striatum‐occipital lobe)/occipital lobe. RESULTS Reduced binding potential of striatal dopamine D2 receptors was found in the 3 symptomatic HD patients. The DAT binding potential was reduced in 1 symptomatic HD patient. We also found that the more severe the clinical status, the lower the DAT and D2 receptor binding potentials, and the larger the bicaudate ratio. CONCLUSIONS We showed that the postsynaptic part of the nigrostriatal pathway was involved. The presynaptic part is usually not affected but could occur in very advanced cases. Our findings suggest that SPECT imaging of D2 receptors is useful for diagnosing and monitoring HD.</description><subject>Adult</subject><subject>Benzamides - pharmacokinetics</subject><subject>Corpus Striatum - diagnostic imaging</subject><subject>Corpus Striatum - metabolism</subject><subject>dopa-mine transporter</subject><subject>Dopamine</subject><subject>dopamine D2 receptor</subject><subject>Dopamine Plasma Membrane Transport Proteins - metabolism</subject><subject>Dopaminergic Neurons - diagnostic imaging</subject><subject>Dopaminergic Neurons - metabolism</subject><subject>Female</subject><subject>Humans</subject><subject>Huntington Disease - diagnostic imaging</subject><subject>Huntington Disease - metabolism</subject><subject>Huntington's disease</subject><subject>Huntingtons disease</subject><subject>Male</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Neural Pathways - diagnostic imaging</subject><subject>Neural Pathways - metabolism</subject><subject>Neuroimaging</subject><subject>Neurology</subject><subject>Organotechnetium Compounds - pharmacokinetics</subject><subject>Pyrrolidines - pharmacokinetics</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Receptors, Dopamine D2 - metabolism</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>single photon emission computed tomography</subject><subject>Substantia Nigra - diagnostic imaging</subject><subject>Substantia Nigra - metabolism</subject><subject>Tissue Distribution</subject><subject>Tomography, Emission-Computed, Single-Photon - methods</subject><subject>Tropanes - pharmacokinetics</subject><issn>1051-2284</issn><issn>1552-6569</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtvEzEURi0EoqXwF5AlFnQzg69fMyOxQekLiFKkFBWxsRzbExzmEewZkfx7PKRkware2LLPd23fgxAGkkMa7zY5CEEzKWSVUwKQEyILyHdP0Onx4GlaEwEZpSU_QS9i3BBCgVP2HJ1QSgEqSk7RfPnlcnaHl8No97iv8fDD4YVfhz4OwetBN_ii3-rWdy6svcHLfRxci32Hb8Zu8N166Lu3EV_46HR0L9GzWjfRvXqYz9DXq8u72U02v73-OPswzwxPz8xKa5kouLNWc26NoJSXslqVjpsKalEbYK6shATJ9aqylRFgiE2bRlhOVpSdofND3W3of40uDqr10bim0Z3rx6iAM04Y4-wRKKOySB0CkdA3_6Gbfgxd-shECUlKUU5UeaBM6lEMrlbb4Fsd9gqImuSojZocqMmBmuSov3LULkVfP1wwrlpnj8F_NhLw_gD89o3bP7qw-nS7SIsUzw5xnyTtjnEdfipZsEKo-8W1uiLk-_3i22fF2R88oqnt</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Hwang, Wen-Juh</creator><creator>Yao, Wei-Jen</creator><general>Blackwell Publishing Inc</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>SPECT Study of the Nigrostriatal Dopaminergic System in Huntington's Disease</title><author>Hwang, Wen-Juh ; Yao, Wei-Jen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4671-8dd3574edda44dc5224869b8e4c91f5fc13e8956164ab9d9c51c0d13ec5d40b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Benzamides - pharmacokinetics</topic><topic>Corpus Striatum - diagnostic imaging</topic><topic>Corpus Striatum - metabolism</topic><topic>dopa-mine transporter</topic><topic>Dopamine</topic><topic>dopamine D2 receptor</topic><topic>Dopamine Plasma Membrane Transport Proteins - metabolism</topic><topic>Dopaminergic Neurons - diagnostic imaging</topic><topic>Dopaminergic Neurons - metabolism</topic><topic>Female</topic><topic>Humans</topic><topic>Huntington Disease - diagnostic imaging</topic><topic>Huntington Disease - metabolism</topic><topic>Huntington's disease</topic><topic>Huntingtons disease</topic><topic>Male</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Neural Pathways - diagnostic imaging</topic><topic>Neural Pathways - metabolism</topic><topic>Neuroimaging</topic><topic>Neurology</topic><topic>Organotechnetium Compounds - pharmacokinetics</topic><topic>Pyrrolidines - pharmacokinetics</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Receptors, Dopamine D2 - metabolism</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>single photon emission computed tomography</topic><topic>Substantia Nigra - diagnostic imaging</topic><topic>Substantia Nigra - metabolism</topic><topic>Tissue Distribution</topic><topic>Tomography, Emission-Computed, Single-Photon - methods</topic><topic>Tropanes - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hwang, Wen-Juh</creatorcontrib><creatorcontrib>Yao, Wei-Jen</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hwang, Wen-Juh</au><au>Yao, Wei-Jen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SPECT Study of the Nigrostriatal Dopaminergic System in Huntington's Disease</atitle><jtitle>Journal of neuroimaging</jtitle><addtitle>J Neuroimaging</addtitle><date>2013-04</date><risdate>2013</risdate><volume>23</volume><issue>2</issue><spage>192</spage><epage>196</epage><pages>192-196</pages><issn>1051-2284</issn><eissn>1552-6569</eissn><abstract>ABSTRACT BACKGROUND AND PURPOSE The pathological process of Huntington's disease (HD) preferentially targets spiny neurons in the striatum, with later involvement of the substantia nigra and other structures. The purpose of this study is to investigate the nigrostriatal dopaminergic system in a genetically confirmed HD family. METHODS We used single photon emission computed tomography (SPECT) with the radiotracers [99mTc]TRODAT‐1 and [123I]IBZM to study the binding potentials of dopamine transporter (DAT) and dopamine D2 receptors in the striatum of 3 symptomatic HD patients, 1 mutation‐negative member of the HD family, and 7 healthy controls. Specific binding potentials were calculated as (striatum‐occipital lobe)/occipital lobe. RESULTS Reduced binding potential of striatal dopamine D2 receptors was found in the 3 symptomatic HD patients. The DAT binding potential was reduced in 1 symptomatic HD patient. We also found that the more severe the clinical status, the lower the DAT and D2 receptor binding potentials, and the larger the bicaudate ratio. CONCLUSIONS We showed that the postsynaptic part of the nigrostriatal pathway was involved. The presynaptic part is usually not affected but could occur in very advanced cases. Our findings suggest that SPECT imaging of D2 receptors is useful for diagnosing and monitoring HD.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>22211920</pmid><doi>10.1111/j.1552-6569.2011.00671.x</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1051-2284
ispartof Journal of neuroimaging, 2013-04, Vol.23 (2), p.192-196
issn 1051-2284
1552-6569
language eng
recordid cdi_proquest_miscellaneous_1434033432
source MEDLINE; Access via Wiley Online Library
subjects Adult
Benzamides - pharmacokinetics
Corpus Striatum - diagnostic imaging
Corpus Striatum - metabolism
dopa-mine transporter
Dopamine
dopamine D2 receptor
Dopamine Plasma Membrane Transport Proteins - metabolism
Dopaminergic Neurons - diagnostic imaging
Dopaminergic Neurons - metabolism
Female
Humans
Huntington Disease - diagnostic imaging
Huntington Disease - metabolism
Huntington's disease
Huntingtons disease
Male
Medical research
Middle Aged
Neural Pathways - diagnostic imaging
Neural Pathways - metabolism
Neuroimaging
Neurology
Organotechnetium Compounds - pharmacokinetics
Pyrrolidines - pharmacokinetics
Radiopharmaceuticals - pharmacokinetics
Receptors, Dopamine D2 - metabolism
Reproducibility of Results
Sensitivity and Specificity
single photon emission computed tomography
Substantia Nigra - diagnostic imaging
Substantia Nigra - metabolism
Tissue Distribution
Tomography, Emission-Computed, Single-Photon - methods
Tropanes - pharmacokinetics
title SPECT Study of the Nigrostriatal Dopaminergic System in Huntington's Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A59%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SPECT%20Study%20of%20the%20Nigrostriatal%20Dopaminergic%20System%20in%20Huntington's%20Disease&rft.jtitle=Journal%20of%20neuroimaging&rft.au=Hwang,%20Wen-Juh&rft.date=2013-04&rft.volume=23&rft.issue=2&rft.spage=192&rft.epage=196&rft.pages=192-196&rft.issn=1051-2284&rft.eissn=1552-6569&rft_id=info:doi/10.1111/j.1552-6569.2011.00671.x&rft_dat=%3Cproquest_cross%3E1434033432%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1325608585&rft_id=info:pmid/22211920&rfr_iscdi=true